CAN SOME ONE CHECK THIS OUT I AM DRIVING IF THIS IS US WE ARE RICH.



HIV Cure & Treatment Found? FDA Approves Gene-Editing Method

Using the technique developed by Richmond's Sangamo BioSciences Inc. to cause mutation, HIV present in the body wouldn't be able to enter the T cells and replicate in them. Therefore, the immune system of the HIV-infected patients will remain uncompromised. The T-cell is a type of WBC that finds, destroys and stores information of foreign antigens that enter the human body.

http://www.latinoshealth.com/articles/5171/20150330/hiv-cure-treatment-found-fda-approves-gene-editing-method.htm

THIS IS HUGE

$$$$$ We are getting an extra 22.75 millions + a royalty of net annual worldwide sales also up to 1,125 million as development cost to develop the 3 ADCs they are license to.


OXIS International, Inc. (OTCMKTS:OXIS) Subsidiary Executes Deal With MCIT
BY JOHNIE ZIGLER • MARCH 25, 2015
OXIS International, Inc. (OTCMKTS:OXIS)’s wholly owned subsidiary arm called as Oxis Biotech, Inc. announced the completion of a definitive licensing and development deal with MultiCell Immunotherapeutics, Inc. . The deal revolves around the development functions of certain antibody-drug conjugates which are considered to be beneficial for treating multiple myeloma and triple-negative breast cancer.

The terms

As per the agreed deal, MultiCell Immunotherapeutics will work on three ADC product candidates. These will have OXIS’ lead drug candidates OXS-4235 and OXS-2175. Oxis International subsidiary paid a license fee of $500,000 to MCIT. It will also reimburse MultiCell Immunotherapeutics up to $1.125 million as development costs to develop the three ADCs that are licensed to the company. In event of completion of all clinical development, OXIS will make an additional payment of $22.75 million to MCIT. It will also pay a royalty of 3% of net annual worldwide sales.

The technology

MultiCell Immunotherapeutics proprietary ADC technology works on the concept of multivalent, cleavable linkers. They enable tethered drugs to come out extracellularly or intracellularly after they are bounded with the antibody to the target cell. Moreover, the linkers are formulated to attach multiple drugs and then to release them in the original form without any modification. Oxis International subsidiary will significantly benefit from the new technology.

The scope

OXIS International, Inc. (OTCMKTS:OXIS) subsidiary CEO Anthony Cataldo said that the management is pleased to include the new technology in the portfolio. The antibody-drug conjugates can be termed as the wave of the future. The new technology permits the company to leverage its existing technologies including OXS-4235 and OXS-2175 as targeted therapies. This will result in better yield and efficacy as the company develops its therapies. As per a report, there were more than 200,000 new cases of invasive breast cancer recorded in last year in the U.S. which indicates the need of an effective treatment.

http://traders350.com/oxis-international-inc-otcmktsoxis-subsidiary-executes-deal-with-mcit/722674/

They have it just not saying it yet

Miami, Florida –24th March 2015 – (TechSonian) – OXIS International, Inc. (OTCMKTS:OXIS) reported the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc concerning the development of certain antibody-drug conjugates. These ADCs are thought to be useful for the cure of triple-negative breast cancer, and multiple myeloma and associated osteolytic lesions which are significant unmet medical needs.

VERY NICE These ADCs are thought to be useful for the cure of triple-negative breast cancer

http://www.techsonian.com/penny-stocks-alert-oxis-international-oxis-infineon-technologies-ifnny-hitachi-hthiy-green-technology-solutions-gtso/12441216/

ENERGY AND GAS SOUNDS LIKE A GOOD PLAN

https://www.google.com/finance?q=OTCMKTS%3ASMNG&ei=iJYSVbnGGu2osgfqsIGoCA

Apple Inc (AAPL) Stock Expected To Soar With Higher In 2015; $160 Price Target Rests On Apple Watch, iPhone Performance

http://au.ibtimes.com/apple-inc-aapl-stock-expected-soar-higher-2015-160-price-target-rests-apple-watch-iphone-performance

VERY NICE

Let's see 1,2,3, or 4 years waiting I think is payday time ??

My account still up 650 % on this one it didn't fade like other times. I guess we'll find out one of these days. GLTYA

My shares are for sale at .10 cents if they want it.

Up 49,000 too nice

Healthy green apple

MORE GOOD NEWS OUT TODAY.

http://www.baystreet.ca/viewarticle.aspx?id=427025

Biotechnology And The Road To Innovation: What Companies Are Pushing New Innovation In Today's Market?



[ACCESSWIRE]
CORAL GABLES, FL / ACCESSWIRE / March 19, 2015 / Globally, the market for biotechnology has been growing at a rate of over 10% annually according to a report from IBISWorld. Annual revenue is on the cusp of breaking $290 Billion and has many sub sectors contributing to its further expansion. Industry firms have thrived as technological advances have facilitated new discoveries and ignited higher demand from firms in the pharmaceuticals and agricultural sectors. According to the report, industry growth is forecast to continue "skyrocketing in the next five-year period" where investment in biotechnology from around the world increases, particularly from emerging economies.

From new drug discovery from companies like Oxis International (OTCQB:OXIS) and Rich Pharmaceuticals (OTCQB:RCHA) to advanced technology like that of PositiveID Corp (OTCQB:PSID), the marketplace for biotech and biotech stocks continues to grow.

In a recent press release, PositiveID announced that it had filed an additional patent for its Firefly DX Real Time PCR System. If you're unfamiliar with what this is, Firefly Dx is designed to provide "real-time, accurate diagnostic results using polymerase chain reaction (PCR) chemistry in a handheld device." According to the company, this leads to treatment scenarios at the point of need that are not possible with existing systems and it also provides results in less than 20 minutes. Many uses include monitoring for pathogenic outbreaks like the recent Ebola epidemic, agriculture screening, and biological agents associated with weapons of mass destruction. According to Research and Markets, the Global PCR market is projected to reach approximately $27.4 Billion in 2015. Recent trading in the market for PSID has begun to pick up steam as above average trading volume has seen this stock as high as $0.029 just a few days ago.

From a medical perspective, a company like Oxis International is taking a different angle on biotech and focusing on medical applications for certain cancers using cannabinoids. In fact, just last week the company announced the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates thought to be useful for the treatment of triple-negative breast cancer, and multiple myeloma. Since kicking off the year, Oxis International has also begun to see an increase in trading volume. Since the beginning of January, the stock has seen prices as high as $0.06 and trading topping out at nearly 18 million shares on certain instances.

In similar fashion Rich Pharmaceuticals is in the clinical stages of developing therapies concentrating initially on the treatment of Acute Myelocytic Leukemia. Since seeing explosive price movement earlier in February, it has seen considerable amounts of consolidation back to a level it was trading at prior to that price jump. In recent news, management announced that Dr. Chittima Sirijerachai has committed to becoming a principal investigator for the upcoming AML clinical trial utilizing Rich's flagship compound RP-323.

ABOUT US:

www.DailyStockReporter.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals www.DailyStockReporter.com is often in the know of several large investor awareness campaigns being deployed. Timing is everything when trading Penny Stocks. Subscribe to the www.DailyStockReporter.com newsletter and start receiving daily alerts. Subscribe Here: http://www.DailyStockReporter.com/.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. EGM FIRM INC which owns www.DailyStockReporter.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. EGM FIRM INC which owns www.DailyStockReporter.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. EGM FIRM INC which owns www.DailyStockReporter.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

CONTACT:

Company: DailyStockReporter.com
Contact Name: Adam Heimann
Contact Email: adam@egmfirm.com

To the moon baby

Simply the best

Taking over the world baby

THIS IS IT Under a licensing and development agreement Oxis signed with MultiCell Immunotherapeutics Inc., MultiCell will create three novel antibody-drug conjugates using MultiCell's proprietary platform technology. Antibody-drug conjugates, or ADCs, are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for cancer.

GOOD NEWS Cancer treatment candidates from Tampa biotech firm advance

http://www.bizjournals.com/tampabay/blog/morning-edition/2015/03/cancer-treatment-candidates-from-tampa-biotech.html

Partners
http://www.multicelltech.com/about-us/partners/

Pipeline
http://www.multicelltech.com/therapeutic-pipeline/

Cancer
http://www.multicelltech.com/innovative-approaches-for-medical-needs/cancer/

Patents
http://www.multicelltech.com/therapeutic-pipeline/published-patents/

This is huge news for multicell

Go mcet

5 years waiting. It is coming

Good news

Nothing like a green apple

I am sorry I think We Are Doomed. The owner is selling the website for $ 477.00 dollars.

http://www.strategicminingcorp.com/

https://sedo.com/search/details.php4?partnerid=14456&language=us&et_cid=13&et_lid=17473&domain=strategicminingcorp.com&et_sub=1006&origin=parking

5 years waiting hopefully pays off.

5 years waiting

Weeeeeeeee

according to the economic calendar is this week on friday.

http://www.fredericknewspost.com/news/economy_and_business/finance/economic-calendar/article_2b1c2391-ac70-57e4-91c2-2c4906bb414c.html

Thank you.

Earnings this Friday

Earnings this Friday

http://www.itbusinessnet.com/article/Fatigue-Therapeutics-Pipeline-Drugs--Companies-Review-H1-2015-Market-Research-Report-3748223


atigue Therapeutics Pipeline Drugs & Companies Review H1 2015 Market Research Report
RnRMarketResearch.com adds "Fatigue - Pipeline Review, H1 2015" to its store. This provides an overview of the Fatigue's therapeutic pipeline.
FEBRUARY 11, 2015 --

DALLAS, Feb. 11, 2015 /PRNewswire-iReach/ -- The report "Fatigue Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Fatigue. Fatigue is a feeling of weariness, very tired, prolonged mental or physical work and lack of energy. There is various cause of fatigue that includes anemia, diabetes, thyroid disease, heart disease, COPD and sleep disorders. Fatigue is common. About 20% of Americans claim to have fatigue intense enough to interfere with living a normal life.
Photo - http://photos.prnewswire.com/prnh/20150211/174885
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report also reviews key players involved in the therapeutic development for fatigue and special features on late-stage and discontinued projects. Companies discussed in this fatigue pipeline review H1 2015 report include Biovista Inc., Dimerix Bioscience Pty Ltd, Hemispherx Biopharma, Inc., Merz Pharmaceuticals GmbH, MultiCell Technologies, Inc., PharmaLundensis AB, Teva Pharmaceutical Industries Limited. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269566 . (This is a premium report priced at US$2000 for a single user License.)
Fatigue is a symptom that usually has some underlying cause. Symptoms are weakness, lack of energy, constantly tired or exhausted, lack of motivation, difficulty concentrating and difficulty starting and completing tasks. The treatment for fatigue depends upon the cause. Some treatments for conditions that cause fatigue include medications, antibiotics, vitamins, and exercise. The report also provides complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.This report also review the Botulism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Provide a detailed assessment of monotherapy and combination therapy pipeline projects and also provide strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies.
Scope of this report are: a snapshot of the global therapeutic landscape of Fatigue; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Fatigue and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; A review of the Fatigue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Fatigue pipeline on the basis of target, MoA, route of administration and molecule type as well as Latest news and deals relating related to pipeline products.
Explore more reports on Diseases & treatment at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment .
More reports on Infectious Diseases & treatment Market:
Peritoneal Cancer Pipeline Review, H1 2015
This report provides comprehensive information on the therapeutic development for Peritoneal Cancer. Companies discussed in this report include AbbVie Inc., Acceleron Pharma, Inc., Adaptimmune Limited, Advanced Accelerator Applications SA, Amgen Inc., Astellas Pharma Inc., Astex Pharmaceuticals, Inc., AstraZeneca PLC, Basilea Pharmaceutica AG, Bayer AG, BioMarin Pharmaceutical Inc., Bionomics Limited, Boehringer Ingelheim GmbH, Celldex Therapeutics, Inc., Celsion Corporation, Cerulean Pharma, Inc., Clovis Oncology, Inc., Corcept Therapeutics Incorporated, CritiTech, Inc., CTI BioPharma Corp., Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd., Galena Biopharma, Inc., Genelux Corporation, Genentech, Inc., GlaxoSmithKline plc, Glycotope GmbH, Hemispherx Biopharma, Inc., ImmunoGen, Inc., Immunotope, Inc., Immunovaccine, Inc., Johnson & Johnson, Lee's Pharmaceutical Holdings Limited, MabVax Therapeutics Holdings, Inc., MedImmune, LLC, Merck & Co., Inc.
Perennial Allergic Rhinitis Pipeline Review, H1 2015
This report provides comprehensive information on the therapeutic development for Perennial Allergic Rhinitis. Companies discussed in this report include Adamis Pharmaceuticals Corporation, FAES Farma SA, GenMont Biotech Inc., GlaxoSmithKline plc, Hanmi Pharmaceuticals, Co. Ltd., Merck & Co., Inc., Pfizer Inc., Shionogi & Co., Ltd., VentiRx Pharmaceuticals, Inc.
Kaposi's Sarcoma Pipeline Review, H1 2015
This report provides comprehensive information on the therapeutic development for Kaposi's Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kaposi's Sarcoma and special features on late-stage and discontinued projects. Companies discussed in this report include Delenex Therapeutics AG.
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on sales@rnrmarketresearch.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.
Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, sales@rnrmarketresearch.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research

Copyright 2014 PR Newswire. All Rights Reserved
Page: 1
Related Keywords:Manufacturing, Applications, Manufacturing/Production, Manufacturing, Database, Internet, Business Issues, Other, Business Intelligence, Administration, Internet Server Applications, E-mail, IT Management, Inc., IT (Information Technology), Medicine, Disease, Cancer, Surgery, Medication, Vitamins/Nutrition, Science, Medical, Biology, Computer Science,
Source:PR Newswire. All Rights Reserved

221,000,000 millions on the bid something fishy is going on here.

Enter Symbol(s):
e.g. YHOO, ^DJI Symbol Lookup | Financial Search
WEST > SEC Filings for WEST > Form 8-K on 4-Mar-2015 All Recent SEC Filings
Show all filings for ANDALAY SOLAR, INC.
Form 8-K for ANDALAY SOLAR, INC.

4-Mar-2015

Entry into a Material Definitive Agreement, Financial Statements and Exhibits


Item 1.01 Entry into a Material Definitive Agreement
The Loan and Security Agreement (the "Agreement") among Alpha Capital Anstalt ("Alpha"), Andalay Solar, Inc., and Collateral Services LLC dated as of September 30, 2013 had expired as of December 31, 2014. On February 27, 2015 we executed a Second Amendment to the Loan and Security Agreement (the "Amendment") extending the term to February 29, 2016. We also provided for the note to be convertible into our commons shares pursuant to a newly issued one year Convertible Note (the "Note"). The Amendment provides for the $500,000, plus accrued interest, under the Agreement to be exchanged for the new amount of $500,000, plus accrued interest, under the Note. The effective interest rate was reduced from 12% under the Agreement to 8% under the Note.

The Note is convertible to shares of common stock of Andalay Solar, Inc. at a conversion price of $.01 per share, subject to adjustment under certain conditions. The Note contains usual and customary covenants and other terms and conditions which have previously been agreed to with Alpha pursuant to prior note issuances.

The Amendment provides that the Agreement be extended for one year, that no further borrowing is permitted under the Agreement, that the outstanding amounts due under the Agreement be exchanged for a new convertible note, and that the conversion price of the existing outstanding convertible note between Andalay Solar, Inc. and Alpha Capital Anstalt dated February 25, 2014 for the principal amount of $200,000 be reduced from $0.02 per share to $0.01 per share of common stock of Andalay Solar, Inc. The principal owing under the 2014 note has been reduced by $80,000 to $120,000.

The preceding description of the Note and the Amendment does not purport to be complete and is qualified in its entirety by reference to the Note and the Amendment, which are attached hereto as Exhibit 10.1 and 10.2 respectively, and incorporated herein by reference.



Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

The following Exhibits are filed as part of this Report.

Because they are Gov cash cows. GO FNMA

Apple Inc able to raise dividend by 50% as soon as April 2015, RBC Capital Markets says

http://business.financialpost.com/2015/02/19/apple-inc-able-to-raise-dividend-by-50-rbc/?__lsa=af38-c35a

It's coming patience is a virtue.

I love green apples

Do we have anything to do with first solar.?